State the posture before the timeline. Vertex is, by a wide margin, the largest assignee in the CFTR-modulator patent record, and its protection is not one patent but a stack laid down over more than a decade. The early layer includes US8513282B2, "Modulators of cystic fibrosis transmembrane conductance regulator" (issued August 20, 2013) — a composition-class grant on CFTR-modulating compounds. The recent layer includes US12186306B2, "Methods of treatment for cystic fibrosis" (issued January 7, 2025; CPC A61K 31/4375) — a method-of-treatment grant on how the drugs are used.

The distinction drives the expiry math. Composition-of-matter claims, like the 2013 modulator grant, typically have the earliest priority and are the first to lapse; they are also the hardest to design around while live. Method-of-treatment and formulation claims, filed later, carry later priority dates and can keep protecting a specific dosing regimen or combination after the core compound claims expire. Account for that layering before calling any single expiry date "the" cliff — the franchise cliff is a staircase, not a step.

“The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR.”— U.S. Patent No. 8,513,282 source

Be precise about what later grants do and do not extend. A method-of-treatment grant issued in 2025 does not revive an expired composition claim; it protects the specific claimed method. So a generic that practices an unclaimed regimen with an off-patent compound may avoid the later method claims even while the composition is open. The exclusivity question is therefore claim-by-claim and regimen-by-regimen, not franchise-wide.

There is also a modality-shift signal in the record. Translate Bio's US12195505B2, "Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR" (issued January 14, 2025; CPC C07K 14/4702), claims an entirely different approach — delivering mRNA that encodes CFTR rather than a small-molecule modulator. That is a different IP lane targeting the same disease, and it matters for exclusivity because it represents potential competition that does not infringe Vertex's small-molecule claims at all.

For an exclusivity analysis, the discipline is to account for patent-term adjustments and any pediatric exclusivity before drawing the timeline, then to map each claim type to its own expiry. The early composition grants set the floor; the method and formulation grants extend the ceiling on specific uses; and adjacent-modality patents (like nebulized-mRNA CFTR) define competition that sits outside the small-molecule estate entirely.

The reporter's bottom line: Vertex's CF exclusivity is a function of layering. No single grant — not the 2013 composition claim, not the 2025 method claim — tells the whole story. The staircase of priority dates and claim types is the structure, and a credible cliff analysis walks each step, accounts for term extensions, and notes that a different modality could compete without ever touching the modulator claims.